查詢結果分析
相關文獻
- 人類白血球單一抗原抗體試驗對於血小板輸注無效病患尋找HLA配對相合血品之應用與成效評估
- 再談減除白血球血小板的好處
- 減除白血球血品的實證醫學
- Cytokines and Growth Factors Secreted by Vero Cells Destined for Embryo Cocultures
- 新生兒異族免疫性血小板低下症
- Idiopathic Thrombocytopenic Purpura Preceding Malignant Lymphoma: Report of One Case
- Synthesis and Antiplatelet Activity of 5-Methyl-2-Furyl Methyl Ketone Phenylhydrazones and Related Compounds
- Synthesis and Antiplatelet Activity of 1,3-Disubstituted 5-Methylthieno[3,2-c]Pyrazoles
- 誘導血小板聚集觀察腦中風
- 九節木之活血化瘀活性分析
頁籤選單縮合
| 題 名 | 人類白血球單一抗原抗體試驗對於血小板輸注無效病患尋找HLA配對相合血品之應用與成效評估=The Application and Outcome of HLA Single Antigen Flow PRA Test to Identify Compatible Platelet Units for Patients with Platelet Transfusion Refractoriness |
|---|---|
| 作 者 | 林志璞; 林美華; 葉如惠; 王廷瑞; | 書刊名 | Journal of Biomedical & Laboratory Sciences |
| 卷 期 | 36:4 2024.12[民113.12] |
| 頁 次 | 頁181-195 |
| 分類號 | 415.652 |
| 關鍵詞 | 血小板; HLA配對相合血小板; 人類白血球單一抗原抗體檢驗; 血小板增加指數; 血小板輸注無效; Platelet; HLA-matched platelet; Single antigen bead assay; Donor-specific antibody; Corrected count increment; CCI; Platelet transfusion refractoriness; PTR; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 背景 : 隨著醫療技術日漸發達,對於血液腫瘤病患、骨髓移植者之後續支持性治療或是先天血小板低下 症狀者,血小板血品的輸注仍是能夠提升血小板計數並降低出血風險的方法。然而,隨著許多受血者須長 期輸注血小板,也常造成血小板輸注無效(Platelet Transfusion Refractoriness,PTR)之狀況。臨床上為了 避免血小板輸注無效造成醫療資源的浪費,通常有下列方法尋找因免疫性因素引發輸注無效之受血者適合 輸注之血小板,例如:交叉相合(Cross-matched compatible)血小板、人類白血球抗原配對(HLA-matched) 血小板等。本研究應用 HLA 抗體鑑定於體內含有 HLA 抗體而使血小板輸注無效之受血者,藉由分析受 血者血清 HLA 抗體分型,避開血品與受血者對應到之 HLA 抗體,選擇相容 HLA 型別提升尋找適合血品 機率、並期望能夠提升輸血安全與減少醫療資源浪費。 方法 : 受試者進行 HLA 抗體鑑定並統計 HLA 抗體型別,依受試者本身 HLA 型別、抗體資訊預定血小 板,並於血小板輸注前、後 1 個小時採集周邊血計算血小板上升指數,並評估血小板輸注成效。 結果 : 根據實驗數據統計,在參加本研究計畫受試者所輸注的所有 HLA 相合血小板血品或交叉配對血小 板血品,A 等級血品占約 6%,而次等級 B1U 至 B2UX 血品占約 59%,輸注成效依據 CCI 之計算結果(平 均 1-hr CCI>7500)成效良好。最後約 35%為等級介於 C 至 D 之血小板血品,臨床上認為 C 等級以下血 品輸注成效與隨機血小板(R)無顯著差異,但根據本研究結果顯示,若輔以 HLA 單一抗原抗體檢驗,能夠 避開受血者血清中對應抗體且 HLA 型別不合的 C 等級血小板,也能夠有良好的輸注成效(平均 1-hr CCI>7500)。 結論 : 我們能夠藉由本研究之結果觀察到 HLA 單一抗原抗體檢驗在血小板輸注尋找血品的過程中扮演 良好的輔助角色,除了可以避免傳統僅尋找 HLA 型別一致血品耗時較長卻不敷臨床使用需求的缺點之外, 也能夠追蹤受試者體內 HLA 抗體的變化,進一步避免使用傳統不靈敏方法尋找之交叉相合血小板造成輸 注無效與醫療資源的浪費。 |
| 英文摘要 | Background: With the development and innovation of medical technology, transfusion of platelet products is still a necessary treatment to prevent bleeding tendency and some adverse clinical outcomes for patients who get blood cancer or bone-marrow transplantation. However, the incidence of platelet transfusion refractoriness also gets raised due to long-term repetition of platelet transfusion to these recipients. Immune reasons such as ABO blood group incompatible, presence of HPA and HLA antibodies can show little to no increase in platelet count at 1 hour post transfusion while non-immune causes usually have decrease in platelet count post 24 hours. Recently, blood centers and medical technologists introduce single antigen flow panel-reactive antibodies test to identify antibodies against HLA in patients’ serum and HLA matchmaker software to calculate serologic “eplet score”. By the application of these methods medical technologists can obtain HLA antigen-restricted platelets which avoid the HLA antibodies that the recipients have in a “virtual”, “epitopebased” crossmatch. Methods: This study applied human leukocyte single antigen antibody assay to recipients with pre-formed HLA antibodies, which made platelet transfusion refractoriness. By analyzing the HLA antibodies panel of the recipient's serum, the HLA type of the donor can be avoided when looking for a compatible blood product. The CBC data was collected before platelet transfusion and post 1 hour of platelet transfusion to calculate the CCI value to evaluate the effectiveness of different platelet products. Results: According to experimental data statistics, in all HLA-matched platelet products or cross-matched platelet products transfused to the participants of this research project, A-grade products accounted for about 6%, and B1U to B2UX grade products accounted for about 59%, with good transfusion efficacy according to the calculation results of CCI. Finally, about 35% were blood products of grades between C and D. In clinical practice, it is believed that the transfusion efficacy of blood products below grade C is not significantly different from that of random platelets (R). However, according to the results of this study, if HLA single antigen antibody testing is used in addition, the C-grade blood products that are not compatible with the HLA type of the serum of the recipient can also have good transfusion efficacy. Conclusion: HLA single antigen antibody testing plays a good auxiliary role in the process of finding blood products for platelet transfusion. In addition to avoiding the disadvantage of traditional methods that only look for blood products with the same HLA type, which is time-consuming and cannot meet the clinical needs, it can also track the changes of HLA antibodies in the body of the participants. Further, it can prevent the transfusion failure and waste of medical resources caused by the cross-matched platelets found by the traditional insensitive methods. |
本系統中英文摘要資訊取自各篇刊載內容。